The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Serum has a capacity of 250-275 million whereas Bharat Biotech has a capacity of 50-60 million
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Subscribe To Our Newsletter & Stay Updated
